0
Abstract: Poster Presentations |

LONG-TERM HEMODYNAMIC IMPROVEMENTS IN PULMONARY HYPERTENSION WITH AMBRISENTAN THERAPY FREE TO VIEW

James R. Klinger, MD*; for the ARIES Study group
Author and Funding Information

Rhode Island Hospital, Providence, RI


Chest


Chest. 2009;136(4_MeetingAbstracts):56S. doi:10.1378/chest.136.4_MeetingAbstracts.56S-b
Text Size: A A A
Published online

Abstract

PURPOSE:  Ambrisentan (ABS) is an ETA-selective endothelin receptor antagonist approved for the treatment of pulmonary arterial hypertension (PAH). Patients in the placebo-controlled, 12-week PAH studies (ARIES-1 and ARIES-2) continued treatment with ABS in a long-term study, ARIES-E. This post-hoc analysis examined hemodynamic changes following treatment with long-term ambrisentan monotherapy (2.5, 5, or 10 mg oral once-daily).

METHODS:  Sixty-eight patients who received long-term ABS treatment in the ARIES-E study had post-baseline right heart catheterization (RHC) data; 58 of these 68 patients (85%) were receiving ABS monotherapy. Historical baseline hemodynamic data were assessed prior to the first dose of ABS (mean = 2.8 ± 3.7 months; median = 1.4 months) and follow-up RHC data was collected at various intervals after the first dose of ABS (mean = 15.4 ± 8.5 months; median = 13.5 months).

RESULTS:  Baseline hemodynamic data were consistent with moderate PAH; mean pulmonary arterial pressure (mPAP) = 50.8 ± 1 2.8 mmHg; cardiac index = 2.5 ± 0.7 L/min/m2; right atrial pressure = 7.7 ± 4.8 mmHg; pulmonary vascular resistance (PVR) = 856 ± 488 dyn×s×cm-5. Clinically relevant improvements were observed for mPAP (−8.2 mmHg; 95% CI : −11.0 to −5.5), cardiac index (+0.5 L/min/m2; 95% CI :0.3 to 0.7) and PVR (−297 dyn×s×cm-5; 95% CI: −384 to −200). Right atrial pressure did not change significantly with long-term treatment (−0.1 mmHg; 95% CI: −1.7 to 1.4).

CONCLUSION:  Clinically relevant improvements in mPAP, cardiac index, and PVR, were observed in PAH patients receiving long-term treatment with ambrisentan.

CLINICAL IMPLICATIONS:  Ambrisentan may provide sustained pulmonary hemodynamic benefits for patients with PAH.

DISCLOSURE:  James Klinger, Grant monies (from industry related sources) Gilead, Actelion, Lilly, Pfizer; Consultant fee, speaker bureau, advisory committee, etc. Gilead, Actelion, United Therapeutics; No Product/Research Disclosure Information

Tuesday, November 3, 2009

12:45 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543